Cited by 114HER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyBreast Cancer Treatment Studies

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Lapatinib for Advanced or Metastatic Breast Cancer

Open access

Opdam, Frans L., Guchelaar, Henk-Jan, Beijnen, Jos H., Schellens, Jan H.M.·2012·The Oncologist

DOI 10.1634/theoncologist.2011-0461PMC PMC3336826

Open this paper in CoChat — free account

Abstract

Lapatinib is a potent reversible and selective inhibitor of the tyrosine kinase domains of epidermal growth factor receptor and human epidermal growth factor receptor (HER)-2 that exerts its action by competitive binding to the intracellular ATP-binding site of the receptor. It is registered for the treatment of advanced or metastatic HER-2+ breast cancer in combination with capecitabine and for hormone receptor–positive breast cancer in combination with an aromatase inhibitor. Lapatinib administered orally once daily is moderately to well tolerated, with rash and gastrointestinal adverse events as the main toxicities. In studies on the efficacy of lapatinib, direct comparisons between lapatinib and trastuzumab are lacking. Results of ongoing randomized phase III studies with lapatinib or trastuzumab in combination with taxanes as first-line agents for metastatic breast cancer as well as in the neoadjuvant and adjuvant settings are awaited.

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2011-0461

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,458
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D. Y., Hassell, A. M., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K. E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,125
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
Johnston, S. R. D., Pippen, J., Pivot, X. B., Lichinitser, M., Sadeghi, S., Dieras, V. C., Gómez, H., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,023
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Blackwell, K., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G. W., Koehler, M. T., Ellis, C. E., Casey, M., Vukelja, S. J., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 940
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
Cameron, D., Casey, M., Press, M. F., Lindquist, D. L., Pieńkowski, T., Romieu, C. G., Chan, S. Y. T., Jagiełło-Gruszfeld, A., Kaufman, B., Crown, J. P., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9885-0 · Cited by 795
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
von Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Čufer, T., de Jongh, F. E., Maartense, E., Zielinski, C. C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 674
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 671
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K., O’Neil, B. H., Marcom, P. K., Ellis, M. J., Overmoyer, B. A., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
Leo, A. D., Gómez, H., Aziz, Z., Zvirbule, Z., Bines, J., Arbushites, M. C., Guerrera, S., Koehler, M. T., Oliva, C., Stein, S. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2578 · Cited by 417
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
Clayton, A., Danson, S. J., Jolly, S., Ryder, W. D. J., Burt, P. A., Stewart, A. L., Wilkinson, P. M., Welch, R., Magee, B., Wilson, G., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601970 · Cited by 384
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
MEDINA, P., & Goodin, S. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.008 · Cited by 377
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
(2007) · New England Journal of Medicine · doi:10.1056/nejmx070016 · Cited by 350
Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
Cameron, D., Casey, M., Oliva, C., Newstat, B. O., Imwalle, B., & Geyer, C. E. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0181 · Cited by 304
Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy
Pegram, M. D., Pauletti, G. M., & Slamon, D. J. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006111117877 · Cited by 263
An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)
Polli, J. W., Olson, K. L., Chism, J. P., John‐Williams, L. S., Yeager, R. L., Woodard, S. M., Otto, V., Castellino, S., & Thiel-Demby, V. E. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024646 · Cited by 256
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
Xia, W., Liu, L.-H., Ho, P. T. C., & Spector, N. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207166 · Cited by 254
Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.
von Minckwitz, G., Schwedler, K., Schmidt, M., Barinoff, J., Mundhenke, C., Čufer, T., Maartense, E., de Jongh, F. D., Baumann, K., Bischoff, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.021 · Cited by 198
Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients
Koch, K. M., Reddy, N. J., Cohen, R. B., Lewis, N. L., Whitehead, B. P., Mackay, K., Stead, A. G., Beelen, A. P., & Lewis, L. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3285 · Cited by 147
Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib
Teng, W.-C., Oh, J. W., New, L. S., Wahlin, M. D., Nelson, S. D., Ho, H. K., & Chan, E. C. Y. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065839 · Cited by 119
Abstract S3-3: First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer
Baselga, J. M., Bradbury, I., Eidtmann, H., Cosimo, S. D., Aura, C. M., de Azambuja, E., Gómez, H., Dinh, P., Fauria, K., Dooren, V. V., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-s3-3 · Cited by 116
A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies
Burris, H. A., Taylor, C. W., Jones, S. F., Koch, K. M., Versola, M., Arya, N., Fleming, R. A., Smith, D. A., Pandite, L. N., Spector, N. L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0369 · Cited by 99
Advanced breast cancer: diagnosis and treatment
Macbeth, F. R., Champion, A. E., Bennett, A. B., Francis, K. L., Collins, E. C., Berendse, S., Cleves, A., Coles, B., Willis, S., Welton, N. J., et al. (2008) · Bristol Research (University of Bristol) · Cited by 87
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer
Capri, G., Chang, J., Chen, S.-C., Conte, P., Cwiertka, K., Jérusalem, G., Jiang, Z., Johnston, S. R. D., Kaufman, B., Link, J. S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp373 · Cited by 84
Delivery of a Healthy Baby After First-Trimester Maternal Exposure to Lapatinib
Kelly, H., Graham, M. L., Humes, E., Dorflinger, L. J., Boggess, K., O’Neil, B. H., Harris, J., Spector, N. L., & Dees, E. C. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.048 · Cited by 69
Dual HER2-targeted approaches in HER2-positive breast cancer
Ahn, E. R., & Vogel, C. L. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1781-y · Cited by 64
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis
Fleeman, N., Bagust, A., Boland, A., Dickson, R., Dundar, Y., Moonan, M., Oyee, J., Blundell, M., Davis, H., Armstrong, A. C., et al. (2011) · Health Technology Assessment · doi:10.3310/hta15420 · Cited by 63
Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects
Smith, D. A., Koch, K. M., Arya, N., Bowen, C. J., Herendeen, J. M., & Beelen, A. P. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03370.x · Cited by 63
Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC–ESI-MS/MS)
Bai, F., Freeman, B. B., Fraga, C. H., Fouladi, M., & Stewart, C. F. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.11.044 · Cited by 57
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan
Midgley, R. S., Kerr, R. S., Flaherty, K. T., Stevenson, J. P., Pratap, S., Koch, K. M., Smith, D. A., Versola, M., Fleming, R. A., Ward, C., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm366 · Cited by 56
Brain metastases in HER2-overexpressing metastatic breast cancer: Comparative analysis of trastuzumab levels in serum and cerebrospinal fluid
Stemmler, H., Schmitt, M., Willems, A., Bernhard, H., Harbeck, N., & Heinemann, V. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.1525 · Cited by 28
Brain metastases (BM) in patients treated with trastuzumab for HER2 overexpressing metastatic breast cancer (MBC): Incidence and survival
Stemmler, H., Kahlert, S., Siekiera, W., Untch, M., Heinrich, B., & Heinemann, V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.1568 · Cited by 9
Ongoing clinical development of lapatinib in HER2-positive (HER2+) metastatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies.
Johnston, S. R. D., Gelmon, K. A., Pivot, X. B., Gradishar, W., Conner, A., Kothari, D., Legenne, P., Leigh, M., O’Rourke, L., & Parikh, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.tps105 · Cited by 1

Flagged first, then by citations

Research works printed but not linked: 13

European Medicines Agency, Tyverb® Summary of Product Characteristics
U.S. Food and Drug Administration, Tykerb® Approval Letter 13–3-2007
U.S. Food and Drug Administration, Tykerb® Approval Letter 29–01-2010
U.S. Food and Drug Administration, Tykerb®. Clinical Pharmacology and Biopharmaceutics NDA review
U.S. Food and Drug Administration Center for Drug Evaluation and Research, Medical Review Tykerb®. 6–3-2007
European Medicines Agency, Assessment Report for Tyverb®. Procedure No. EMEA H/C/795, 2008
National Institute for Health and Clinical Excellence (NICE), Final Appraisal Determination: Lapatinib for the Treatment of Women With Previously Treated Advanced or Metastatic Breast Cancer
National Institute for Health and Clinical Excellence (NICE), Liverpool Review and Implementation Group. Lapatinib and Trastuzumab in Combination With an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor Positive Breast Cancer Which Overexpresses HER-2
CFH-Rapport 11/34: Lapatinib (Tyverb®) in Combinatie met een Aromataseremmer
ClinicalTrials.gov ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2–06/N063D
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
Wikipedia, Bestand:Lapatinib.svg

Sorted by citations

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
Abourehab, M. A. S., Alqahtani, A. M., Youssif, B. G. M., & Gouda, A. M. (2021) · Molecules · doi:10.3390/molecules26216677 · Cited by 211
Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents
Doostmohammadi, A., Jooya, H., Ghorbanian, K., Gohari, S., & Dadashpour, M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01607-9 · Cited by 212
The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
Kurimchak, A. M., Herrera-Montávez, C., Montserrat-Sangrà, S., Araiza-Olivera, D., Hu, J., Neumann-Domer, R., Kuruvilla, M., Bellacosa, A., Testa, J. R., Jin, J., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abn2707 · Cited by 136
Recent strategies to overcome breast cancer resistance
Khan, M. M., Yalamarty, S. S. K., Rajmalani, B. A., Filipczak, N., & Torchilin, V. P. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104351 · Cited by 100
Adherence to targeted oral anticancer medications.
Geynisman, D. M., & Wickersham, K. E. (2013) · PubMed · Cited by 92

See all 114

Authors: Opdam, F. L., Guchelaar, H.-J., Beijnen, J. H., & Schellens, J. H. M.
Affiliations: Leiden University (NL)
Utrecht University (NL)
Corresponding author: Schellens, Jan H.M.
ORCID: Opdam, Frans L.
Guchelaar, Henk-Jan
Beijnen, Jos H.
Schellens, Jan H.M.
Venue: The Oncologist
Publisher: Oxford University Press (OUP)
Published: 2012-04-01
Volume: 17
Issue: 4
Pages: 536-542
ISSN: 1083-7159 (ISSN-L)
1549-490X
DOI: 10.1634/theoncologist.2011-0461
PMC: PMC3336826
OpenAlex: W2169052701
Cited by: 113
References: 33
Citations by year: 2026: 8 · 2025: 10 · 2024: 23 · 2023: 9 · 2022: 12 · 2021: 12 · 2020: 4 · 2019: 6 · 2018: 5 · 2017: 3 · 2016: 2 · 2015: 4 · 2014: 5 · 2013: 8 · 2012: 2
FWCI: 0.66
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: The Oncologist (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Leiden Repository (Leiden University) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: lapatinib, HER2-positive breast cancer, metastatic breast cancer, tyrosine kinase inhibitors, EGFR, HER2, capecitabine, aromatase inhibitors, hormone receptor-positive breast cancer, trastuzumab, drug toxicity, rash, gastrointestinal adverse effects, taxanes
MeSH terms: Lapatinib, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Neoplasm Metastasis, Quinazolines, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lapatinib for Advanced or Metastatic Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks